Movement Alert|Teradata Falls 21.3% in Regular Trading, Q3 Guidance Misses Expectations Despite Strong Q2 Beat

Market Focus
Aug 06

On August 5, Teradata fell 21.3% in regular trading, trading at $27.045/share, with turnover of $166 million. The sharp decline was triggered by disappointing third-quarter guidance issued alongside otherwise strong second-quarter results.

Teradata reported Q2 adjusted EPS of $0.69, significantly beating the consensus estimate of $0.56, while revenue of $410 million also topped the $396.1 million expectation. However, the company guided Q3 revenue midpoint at $395.2 million, below analysts' $403.6 million estimate, and Q3 EPS guidance of $0.55-$0.59 fell short of the $0.62 consensus. Morgan Stanley noted that the better-than-expected first-half performance is not flowing through into the second half, and when compared with other AI beneficiaries where growth is accelerating, Teradata's H2 deceleration stands out. The firm cut its price target to $35 from $40 while maintaining an overweight rating.

Teradata provides a connected multi-cloud data platform for enterprise analytics, serving clients across financial services, government, healthcare, manufacturing, and other sectors globally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10